4.84
+1.04%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanxi Zhendong Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300158.SZ. It has been listed since 7 January 2011. In the fiscal year to 31 December 2024, it reported revenue of CN¥2.97bn and a net loss of CN¥1.33bn. At that date it held total assets of CN¥4.98bn and shareholders' equity of CN¥3.70bn.
Shanxi Zhendong Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and distribution of Chinese traditional medicines and western medicines. The company is headquartered in Changzhi, Shanxi. The company went IPO on 2011-01-07. The firm's main products include anti-tumor series, cardiovascular and cerebrovascular series, anti-infection series, digestive system series, vitamin nutrition series, respiratory system series, antipyretic analgesic series and nervous system series. The firm is also involved in the cultivation of medicinal herbs, as well as the wholesale and retail of pharmaceutical products. The firm distributes its products in domestic market, with North China market as its main market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Jan 2011
- Employees
- 4,123
- Website
- zdjt.com ↗
Leadership
Pay as last reported
- Mr. Kun LiChairman of the Board, since 2024
- Mr. Lianmin YangPresident, Director, since 2021
- Mr. Jianyong ZhanChief Financial Officer
- Mr. Zheyu WangVice President, Secretary of the Board
- Mr. Xufeng WangVice President, Director, since 2006
- Ms. Rongli YouVice President-R&D
- Mr. Jiawen AiDirector
- Ms. Jing LiDirector
- Mr. Zhimin WangDirectorCN¥50,000
- Ms. Lina JinIndependent Director
- Mr. Wanliang LuIndependent Director
- Ms. Xuemei QinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established market presence: Shanxi Zhendong Pharmaceutical Co Ltd has a strong foothold in the pharmaceutical industry.
- Diverse product portfolio: The company offers a wide range of pharmaceutical products, catering to various therapeutic areas.
- Advanced manufacturing facilities: Shanxi Zhendong Pharmaceutical Co Ltd boasts state-of-the-art production facilities, ensuring high-quality and efficient manufacturing processes.
Weaknesses
- Dependence on a few key products: The company heavily relies on a limited number of flagship products, making it vulnerable to market fluctuations.
- Limited international presence: Shanxi Zhendong Pharmaceutical Co Ltd primarily operates within the domestic market, which may limit potential growth opportunities.
- Lack of significant R&D investments: The company's research and development efforts are relatively modest, potentially hindering innovation and product development.
Opportunities
- Growing Chinese pharmaceutical market: With the continuous expansion of the healthcare sector in China, there is an opportunity for Shanxi Zhendong Pharmaceutical Co Ltd to capture a larger market share.
- Emerging markets: The company can explore entering new markets in other countries with increasing healthcare needs, potentially boosting revenue.
- Collaborations and partnerships: Forming strategic alliances with other pharmaceutical companies or research institutions can provide access to new technologies and markets.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, and Shanxi Zhendong Pharmaceutical Co Ltd faces the risk of losing market share to established competitors.
- Regulatory challenges: Compliance with evolving regulations and policies may pose hurdles for the company's operations and product approvals.
- Price pressures: Price control measures imposed by governments and payers can negatively impact the profitability of pharmaceutical companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.